Hong Kong has introduced more measures to incentivize companies to submit their drug marketing applications using the “1+” mechanism it launched last November to speed up the registration of products containing new chemical or biological entities for life-threatening or severely-debilitating diseases.
In addition, the country has implemented a new refuse-to-file (RTF) mechanism to “enhance its timeliness and efficiency” in managing the...